Search

Find exactly what you’re looking for.

Showing 21-28 of 28 results

The FTC has announced the annual updates to the Hart-Scott-Rodino (“HSR”) size thresholds, fees and the daily penalty for HSR violations. The updated thresholds and fees were published in the Federal Register on January 26, 2023 and will take effect on February 27, 2023. See Federal Register...

LATEST UPDATE The FTC has voted to extend the public comment period on its proposed rule to ban employers from imposing non-competes on their workers, and will now be accepting comments on the proposed rule until April 19, 2023. Comments can still be submitted in either writing or online using the...

Class Action Lawsuits Stemming From Use of Session Replay Software Are on the Rise In an effort to enhance customer experience, many businesses and institutions have their public-facing websites collect information with the use of cookies, web beacons, chat bots, and/or “session replay” software...

Saul Ewing is a proud sponsor of the M&A East Conference held by the Philadelphia Chapter of the Association of Corporate Growth. M&A East attracts top strategic and financial dealmakers as well as leading middle market advisors and provides an environment for valuable networking. The conference...

THE CLASS ACTION MECHANISM, RISKS, AND STRATEGIES TO PROTECT YOUR COMPANY Jon Singer, a Partner in the Firm's Class Actions Practice, will be speaking during the Association of Corporate Counsel's July New to In-House Update. This session will provide a high level overview intended to educate new in...

Saul Ewing LLP, a full-service law firm with attorneys in 16 offices, today announced that 59 attorneys from the Firm received the distinguished honor of being recognized for legal excellence and client service by Chambers USA 2022. Several of the Firm’s practice areas also earned high rankings...

Washington, D.C., November 24, 2021 – Saul Ewing LLP served as counsel to Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the successful completion today of its previously announced $450 million acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The acquisition strengthens Supernus'...

For More Information